Jurnalul de Chirurgie
 Jurnalul de chirurgie
Aparitie trimestriala in a doua luna a trimestrului
Published quarterly in the second month of the quarter
ISSN: 1584 - 9341 Vol.10 Nr.3 - Iulie-Septembrie 2014 | sâmbătă, 23 martie 2019
ISSN: 1584 - 9341 Vol.10 No.3 - July-September 2014
English
British Flag| Romana Romanian Flag
 
Creditare EMC
Colegiul Medicilor
Va invitam sa va inregistrati/abonati la Jurnalul de chirurgie pentru a beneficia de creditare EMC
User

Parola

Tine minte
Ti-ai uitat parola?
Syndicate

Advertisement

Elmed

Estima

Liamed

Listare E-mail

PHARMACOTHERAPY IN ADVANCED THYROID CANCER
Voichiţa Mogoş
Clinic of Endocrinology, „St. Spiridon” Hospital Iaşi
University of Medicine and Pharmacy „Gr.T.Popa” Iaşi
Jurnalul de chirurgie 2008; 4 (2):78-89
Full text:
Format PDF (Engleză/English)

Abstract:

Thyroid cancers are the most common carcinomas of the endocrine system. Their behavior depends of histology, extension of the disease and patients-related factors. Differentiated thyroid cancers arising from follicular epithelium may be cured with combined surgery and radioiodine therapy. In 10-15 % of cases patients may develop metastases which are cause of death. In advanced differentiated thyroid cancers of follicular origin combined therapy with radioiodine and TSH suppression may result in a long survival if metastases are still iodine avid are made iodine avid by redifferentiation therapy. Classical chemotherapy has no significant effect in differentiated advanced  thyroid cancers. The knowledge regarding genes and gene products involved in cancer development, dedifferentiation, angiogenesis, tumor progression, and apoptosis allowed the development of a new arsenal of therapeutic agents designed to target these elements. Antibodies, small molecules, antisense nucleotides, and other agents directed against RET- RAF-MAPK, the main pathway of tumor initiation and growth or against   other growth factors and their receptors. Most of these therapeutic agents proven to be efficient in preclinical trials and some enter into clinical trials.

KEY WORDS: DIFFERENTIATED THYROID CANCER, RET–PROTOONCOGENE, ONCOGENE INHIBITORS, ANGIOGENESIS INHIBITORS, MODULATORS OF GROWTH AND APOPTOSIS

Correspondence
to: Voichiţa Mogoş, MD, PhD, Professor of Endocrinology, Clinic of Endocrinology, „St. Spiridon” Hospital Iaşi, Independenţei str. No. 1, 700111, Iaşi, Romania



: Creative Commons License
Jurnalul de chirurgie [Journal of Surgery] by Editorial Board, Department of Surgery University of Medicine and Pharmacy Iasi, E. Tarcoveanu, R. Moldovanu is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Based on a work at www.jurnaluldechirurgie.ro.